MedTrace Logo

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

NCT06970145 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-11-18

No results posted yet for this study

Summary

Primary Aim:

To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib .

Secondary Aims:

1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib.
2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease.
3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .

Conditions

  • Craniopharyngiomas

Interventions

DRUG

Anlotinib

Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-25
Primary Completion
2026-04-20
Completion
2028-04-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06970145 on ClinicalTrials.gov